secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001628280-24-013435
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE
--------------------------------------------------------------------------------

- Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.
- Concurrent PIPE of $115.6M upfront (up to $185M total) led by Commodore Capital and TCGX; net proceeds ~$105M.
- Lead asset AVTX-009 (anti-IL-1β mAb, ex-Eli Lilly) is Phase 2-ready for hidradenitis suppurativa; topline data expected 2026.
- Cash runway extended into 2027; board expanded to 9 with appointments of Jonathan Goldman, Aaron Kantoff, Samantha Truex.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/avtx-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-013435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer